Repatriation Reprise: House Bill Offers Tax Breaks For R&D, Manufacturing Investments

21 Mar 2011
News

Cathy Dombrowski cathy.dombrowski@informa.com

Executive Summary

Domestic drug development could be a major beneficiary if Congress enacts legislation that calls for a tax holiday on overseas earnings brought back to the U.S. for job creation.

Already Registered? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

Topics

Industries
BioPharmaceutical

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

BioPharmaceutical

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS053237

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS053237

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

Repatriation Reprise: House Bill Offers Tax Breaks For R&D, Manufacturing Investments

News

Executive Summary

Related Content

Tax Incentives To Spur Innovation: BIO's "Big Ideas" Beyond FDA

Tax Incentives To Spur Innovation: BIO's "Big Ideas" Beyond FDA

So Much Cash For Pharma, But Nowhere To Spend It

So Much Cash For Pharma, But Nowhere To Spend It

Tight Credit Renews Interest In Lowering Tax On Repatriated Income

Topics

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert